JP2011092201A5 - - Google Patents

Download PDF

Info

Publication number
JP2011092201A5
JP2011092201A5 JP2010286755A JP2010286755A JP2011092201A5 JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5 JP 2010286755 A JP2010286755 A JP 2010286755A JP 2010286755 A JP2010286755 A JP 2010286755A JP 2011092201 A5 JP2011092201 A5 JP 2011092201A5
Authority
JP
Japan
Prior art keywords
compound according
compound
oligonucleotide
inhibiting
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010286755A
Other languages
English (en)
Japanese (ja)
Other versions
JP5923241B2 (ja
JP2011092201A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011092201A publication Critical patent/JP2011092201A/ja
Publication of JP2011092201A5 publication Critical patent/JP2011092201A5/ja
Application granted granted Critical
Publication of JP5923241B2 publication Critical patent/JP5923241B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010286755A 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド Expired - Lifetime JP5923241B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50150903P 2003-09-09 2003-09-09
US60/501,509 2003-09-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006526347A Division JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2011274595A Division JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Division JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Division JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2011092201A JP2011092201A (ja) 2011-05-12
JP2011092201A5 true JP2011092201A5 (enExample) 2012-02-16
JP5923241B2 JP5923241B2 (ja) 2016-05-24

Family

ID=34273050

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Country Status (19)

Country Link
US (8) US7494982B2 (enExample)
EP (3) EP3342425B1 (enExample)
JP (10) JP4690324B2 (enExample)
KR (3) KR20060132802A (enExample)
CN (2) CN100393209C (enExample)
AU (2) AU2004271215B2 (enExample)
BR (1) BRPI0414222B8 (enExample)
CA (1) CA2536015C (enExample)
CY (2) CY1120113T1 (enExample)
DK (2) DK1667522T3 (enExample)
ES (2) ES2775525T3 (enExample)
HU (2) HUE048359T2 (enExample)
IL (1) IL173747A (enExample)
MX (1) MXPA06002660A (enExample)
NZ (1) NZ545516A (enExample)
PL (2) PL1667522T3 (enExample)
PT (2) PT3342425T (enExample)
SI (2) SI3342425T1 (enExample)
WO (1) WO2005023994A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023994A2 (en) * 2003-09-09 2005-03-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
DK3296312T3 (da) 2004-07-02 2021-05-03 Geron Corp Syntese af beskyttede 3'-amino-5'-phosphoramidit-nukleosidmonomerer
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
PT2898887T (pt) 2006-10-30 2018-12-20 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
CN103966345A (zh) 2007-02-09 2014-08-06 西北大学 检测细胞内标靶的颗粒
EP2134364B1 (en) * 2007-03-09 2013-02-13 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
DK2476689T3 (en) 2007-05-10 2016-01-18 Agilent Technologies Inc Thiocarbonbeskyttende groups for RNA synthesis
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
TW200927177A (en) * 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
EA201170127A1 (ru) * 2008-07-02 2011-08-30 Сантарис Фарма А/С АНТАГОНИСТЫ РНК, НАЦЕЛЕННЫЕ НА Hsp27
EP2175023A1 (en) * 2008-07-31 2010-04-14 The University of Zurich Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
PL2342360T3 (pl) 2008-10-17 2016-06-30 Geron Corp Sposób identyfikacji wrażliwości pacjenta na terapię hamującą telomerazę
MX2011005429A (es) 2008-11-24 2011-06-21 Univ Northwestern Composiciones de nanoparticulas de arn polivalentes.
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US9744183B2 (en) 2009-07-06 2017-08-29 Wave Life Sciences Ltd. Nucleic acid prodrugs and methods of use thereof
CN102666879B (zh) 2009-10-30 2016-02-24 西北大学 模板化的纳米缀合物
WO2011079290A1 (en) * 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
AU2012236880B2 (en) 2011-03-28 2016-11-17 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (FFPE) samples by quantitative PCR
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
KR102712879B1 (ko) 2012-07-13 2024-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
HK1214293A1 (zh) 2012-10-26 2016-07-22 Geron Corporation C-myc反义寡核苷酸和利用其治疗细胞增殖性疾病的方法
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
DK3495495T3 (da) 2012-11-30 2021-03-22 Geron Corp Diagnostiske markører til behandling af celleproliferative forstyrrelser med telomeraseinhibitorer
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
AP2015008504A0 (en) 2012-12-07 2015-06-30 Geron Corp Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloprolifarative neoplasms
CN105164269A (zh) 2013-02-22 2015-12-16 里兰斯坦福初级大学理事会 与端粒延伸相关的化合物、组合物、方法和试剂盒
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
EP3052512A4 (en) 2013-09-30 2017-02-22 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
CN106535876B (zh) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN113633669A (zh) * 2015-01-05 2021-11-12 株式会社露太利温 使用luterion抑制癌细胞中端粒酶的方法
MX383293B (es) * 2015-04-23 2025-03-13 Geron Corp Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.
EP3124609A1 (en) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
EP3329004B1 (en) 2015-07-29 2020-01-15 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutic oligonucleotides
MA45290A (fr) * 2016-05-04 2019-03-13 Wave Life Sciences Ltd Procédés et compositions d'agents biologiquement actifs
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
KR20250038815A (ko) 2017-04-20 2025-03-19 신테나 아게 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
LT3652187T (lt) * 2017-07-10 2022-01-25 Geron Corporation Patobulintas imetelstato gamybos būdas
AU2018307983B2 (en) 2017-07-28 2024-07-18 Geron Corporation Methods of treating myelodysplastic syndrome
MX2020011570A (es) 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
CA3120704A1 (en) 2018-11-29 2020-06-04 Geron Corporation Methods of treating myelodysplastic syndrome
EP4032551A4 (en) * 2019-09-18 2023-12-20 National University Corporation Tokyo Medical and Dental University NUCLEIC ACID COMPLEX
JP7577742B2 (ja) * 2019-10-28 2024-11-05 ジェロン・コーポレーション 非晶質固体スクシニル化3-(脂肪酸アミド)-2-ヒドロキシ-1-(保護ヒドロキシ)-プロパン塩およびそれらを作製する方法
AU2020375734A1 (en) * 2019-10-28 2022-05-26 Geron Corporation Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same
IL299205A (en) 2020-07-17 2023-02-01 Geron Corp Subcutaneous telomerase inhibitor preparations and methods of using them
CN116917476A (zh) * 2021-03-03 2023-10-20 国立大学法人东京大学 非环式苏氨醇核酸
EP4316495A4 (en) * 2021-03-25 2025-12-31 Aptacure Therapeutics Ltd CONJUGATE OF NUCLEIC ACID MOLECULE HAVING A PROLONGED IN VIVO HALF-LIFE
WO2023141534A1 (en) 2022-01-19 2023-07-27 Northwestern University Agents that target telomerase reverse transcriptase (tert) for treating cancer and sensitizing cancer cells to genotoxic therapy
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) * 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DK0462145T3 (da) 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
EP0537299A1 (en) * 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) * 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6235886B1 (en) * 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
EP0724589B1 (en) * 1993-10-18 2005-12-07 The Walter And Eliza Hall Institute Of Medical Research A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
FI963581L (fi) 1994-03-18 1996-11-08 Lynx Therapeutics Inc Oligonukleotidi-N3'->P5'-fosforiamidaatit: synteesi ja yhdisteet; hybridisaatio ja nukleaasinsieto-ominaisuudet
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
ATE308554T1 (de) 1994-07-07 2005-11-15 Geron Corp Säugetier-telomerase
WO1996014277A1 (en) 1994-11-07 1996-05-17 Hybridon, Inc. Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
PT1210357E (pt) 1999-09-10 2008-06-11 Geron Corp Oligonucleótido-tiofosforamidatos n3'→p5': sua síntese e utilização
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
WO2005023994A2 (en) 2003-09-09 2005-03-17 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
DK3296312T3 (da) 2004-07-02 2021-05-03 Geron Corp Syntese af beskyttede 3'-amino-5'-phosphoramidit-nukleosidmonomerer
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
PT2898887T (pt) 2006-10-30 2018-12-20 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro

Similar Documents

Publication Publication Date Title
JP2011092201A5 (enExample)
JP2007504830A5 (enExample)
JP2016074736A5 (enExample)
JP2019511491A5 (enExample)
JP2019536464A5 (enExample)
JP2013138681A5 (enExample)
JP2013510561A5 (enExample)
JP2008542285A5 (enExample)
EA201070030A1 (ru) Синтез и применение антиинвертированных фосфоротиоатных аналогов кэп-структуры матричной phk
JP2012500197A5 (enExample)
Chakraborty et al. Harnessing the physicochemical properties of DNA as a multifunctional biomaterial for biomedical and other applications
JP2019535839A (ja) 治療剤の送達のためのエクソソーム
JP2009536660A5 (enExample)
JP2012526548A5 (enExample)
JP2012521201A5 (enExample)
JP2011246469A5 (enExample)
RU2013105329A (ru) Молекула одноцепочечной нуклеиновой кислоты для контроля экспрессии генов
JP2010513363A5 (enExample)
JP2009504783A5 (enExample)
JP2008533007A5 (enExample)
AR072858A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
JP2007302689A5 (enExample)
JP2015512943A5 (enExample)
JP2018502956A5 (enExample)
JP2012505657A5 (enExample)